Factors Influencing Decision-Making About the Use of Chemoprevention in Women at Increased Risk for Breast Cancer

Not Recruiting

Trial ID: NCT01399359


RATIONALE: Learning about how patients make decisions about using chemoprevention may help doctors plan treatment in which more patients are willing to choose chemoprevention to reduce their breast cancer risk. PURPOSE: This clinical trial studies factors influencing decision-making about the use of chemoprevention in women at increased risk for breast cancer.

Official Title

A Study to Evaluate Different Decision-Making Approaches Used by Women Known to be at Increased Risk for Breast Cancer

Stanford Investigator(s)

Irene Wapnir, MD
Irene Wapnir, MD

Professor of Surgery (General Surgery)

Allison W. Kurian, M.D., M.Sc.
Allison W. Kurian, M.D., M.Sc.

Professor of Medicine (Oncology) and of Epidemiology and Population Health


Inclusion criteria

   - The participant must be female.

   - The participant must be greater than or equal to 35 years of age.

   - The participant must be English-speaking.

   - The participant must have been identified as being at increased risk for breast cancer
   as determined by the doctor/healthcare professional (HCP) . (Increased risk for breast
   cancer does not have to be based on a Gail score.)

   - During the participant's counseling session, breast cancer risk and the use of SERMs
   for breast cancer risk reduction must have been discussed, as reported by the
   doctor/HCP who conducted the session. Note: This criterion does not apply to
   participants who are asked before the counseling session to participate in the video
   recording component of DMP-1 at the selected NSABP sites.

Exclusion criteria

   - Previous invasive breast cancer of any type.

   - Previous history of ductal carcinoma in situ (DCIS).

   - Previous history of lobular carcinoma in situ (LCIS) if treated with mastectomy,
   radiation therapy, or endocrine therapy.

   - Participation in any other cancer prevention study involving pharmacologic
   intervention(s) or osteoporosis prevention study involving pharmacologic

   - Any history of or current tamoxifen, raloxifene, or other SERM therapy for any reason.
   (Participants are eligible if SERM use has been discussed prior to the counseling
   session as long as SERMs were never used.)


behavioral: Counseling session

other: Questionnaire 1

other: Questionnaire 2

other: online questionnaire

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Cancer Clinical Trials Office

New Trial Alerts

Receive email alerts when trials open to patients.